Harmen Reyngoudt, Pierre-Yves Baudin, Ericky de Caldas de Almeida Araújo, Damien Bachasson, Jean-Marc Boisserie, Kubéraka Mariampillai, Mélanie Annoussamy, Yves Allenbach, Jean-Yves Hogrel, Pierre G Carlier, Benjamin Marty, Olivier Benveniste
BACKGROUND: Finding sensitive clinical outcome measures has become crucial in natural history studies and therapeutic trials of neuromuscular disorders. Here, we focus on 1-year longitudinal data from quantitative magnetic resonance imaging (MRI) and phosphorus magnetic resonance spectroscopy (31 P MRS) in a placebo-controlled study of sirolimus for inclusion body myositis (IBM), also examining their links to functional, strength, and clinical parameters in lower limb muscles. METHODS: Quantitative MRI and 31 P MRS data were collected at 3 T from a single site, involving 44 patients (22 on placebo, 22 on sirolimus) at baseline and year-1, and 21 healthy controls...
April 13, 2024: Journal of Cachexia, Sarcopenia and Muscle